Penn researchers identify novel therapeutic target for kidney cancer

By -

Kidney cancer, also known as renal cancer, is one of the ten most common cancers in both men and women. The American Cancer Society’s most recent estimates state that of the predicted 63,920 new cases of kidney cancer this year, roughly 20% of  patients will die from the disease. By far, the most common type of kidney cancer is renal cell carcinoma (RCC). The majority of RCCs are clear cell RCCs (ccRCCs), a subtype characterized by metabolic alterations, specifically increased carbohydrate and fat storage. More than 90% of ccRCCs have been found to have mutations in the von Hippel-Lindau (VHL) tumor suppressor gene; however, kidney specific VHL deletion in mice does not induce tumorigenesis or cause metabolic changes similar to those seen in ccRCC tumors. So what additional factors are needed for ccRCC tumor formation and progression? A recent study by Penn researchers published in the journal Nature identified the rate-limiting gluconeogenesis enzyme fructose-1,6-bisphosphatase (FBP1) as a key regulator of ccRCC progression.

To better understand ccRCC progression, the study’s first author, Bo Li, a post-doctoral researcher in the lab of Dr. Celeste Simon, performed metabolic profiling on human ccRCC tumors while also analyzing ccRCC metabolic gene expression profiles. Compared to the adjacent normal kidney tissue, ccRCC tumors had increased amounts of metabolites involved in sugar metabolism and significantly lower expression of carbohydrate storage genes, including FBP1. Further investigation revealed FBP1 expression was reduced in almost all tumor samples tested (>600) and reduced FBP1 expression strongly correlated with advanced tumor stage and poor patient survival. Thus, understanding the role of FBP1 in ccRCCs could significantly impact the treatment of this disease.

How do reduced levels of FBP1 promote ccRCC tumor progression? The authors found that FBP1 depletion in ccRCC cells stimulates growth and relieves inhibition of sugar breakdown (glycolysis), which provides energy for the growing cancer cells. In addition, VHL mutations associated with ccRCCs prevent the degradation of a transcription factor that responds to decreases in oxygen, known as hypoxia-inducible factor α (HIFα), thus stabilizing it. Stabilized HIFα does not cause FBP1 depletion, but its activity is tightly regulated by FBP1. This study emphasized the importance of the interaction between HIFα and FBP1, particularly when glucose and oxygen levels are low, for the formation and progression of the ccRCC.

Why is this work so important? Little is known about how changes in cell metabolism contribute to the formation and progression of ccRCC tumors. As stated by Li, “elucidating how FBP1 impacts the altered metabolic and genetic programs of ccRCC improves our knowledge of the molecular details accompanying ccRCC progression, and identifies novel therapeutic targets for this common malignancy.” Future work may focus on identifying how FBP1 is suppressed and whether reversing FBP1 suppression could improve patient outcomes. 

 -Renske Erion

Comments

Post a Comment

Popular posts from this blog

2015 AAAS Science and Technology Policy Forum Summary

By -
I recently had the opportunity to attend the 2015 AAAS Science and Technology Policy Forum in Washington, D.C. This annual meeting brings together a range of academics and professionals to discuss the broad S&T policy landscape. Below are some of my takeaways from the meeting. I hope to have additional comments from other National Science Policy Group members up soon. By Chris Yarosh The talks and panels at the Forum encompassed a huge range of topics from the federal budget and the appropriations outlook to manufacturing policy and, of course, shrimp treadmills . My opinion of the uniting themes tying this gamut together is just that—my opinion— and should only be taken as such. That being said, the threads I picked on in many of the talks can be summarized by three C’s: cooperation, communication, and citizenship . First up, cooperation. Although sequestration’s most jarring impacts have faded, AAAS’s budget guru Matthew Hourihan warns that fiscal year 2016 could ...
Read more

AAAS Forum Take #2

By -
Another point of view of the AAAS Forum by Matthew Facciani: I have provided scientific testimony and met with some of my local legislators, but I’ve never had any formal exposure to science policy. I was really excited to hear about the AAAS Science & Technology Policy Forum to learn more about how scientists can impact policy. The information I absorbed at the conference was overwhelming, but incredibly stimulating. Some of the lectures discussed the budget cuts and the depressing barriers for achieving science policy. However, I felt there was definitely an atmosphere of optimism at the conference and it was focused on how we can create positive change. One of my favorite aspects of the conference were the discussions of how to effectively communicate science to non-scientists. Before we can even have discussions of funding, the general public needs to understand how science works and why basic science is so important. For example, science never proves anything with 100%...
Read more

Dr. Sarah Cavanaugh discusses biomedical research in her talk, "Homo sapiens: the ideal animal model"

By -
Image
Biology and preclinical medicine rely heavily upon research in animal models such as rodents, dogs, and chimps. But how translatable are the findings from these animal models to humans? And what alternative systems are being developed to provide more applicable results while reducing the number of research animals? Image courtesy of PCRM Last Thursday, PSPG invited Dr. Sarah Cavanaugh from the Physicians Committee for Responsible Medicine to discuss these issues. In her talk entitled, “ Homo sapiens : the ideal animal model,” she emphasized that we are not particularly good at translating results from animal models into human patients. Data from the FDA says that 90% of drugs that perform well in animal studies fail when tested in clinical trials.  It may seem obvious, but it is important to point out that the biology of mice is not identical to human biology. Scientific publications have demonstrated important dissimilarities in regards to the pathology of inflammation...
Read more